NasdaqGM:YI - Toekomstschattingen van analisten en financiële gegevens uit het verleden (CNY Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	18,190	N/A	N/A	N/A	1
12/31/2025	16,550	N/A	N/A	N/A	1
12/31/2024	15,061	N/A	N/A	N/A	1
6/30/2024	14,727	-331	30	40	N/A
3/31/2024	14,780	-375	-227	-217	N/A
12/31/2023	14,948	-393	-457	-447	N/A
9/30/2023	14,988	-297	-219	-187	N/A
6/30/2023	14,671	-300	-242	-210	N/A
3/31/2023	14,231	-338	-108	-76	N/A
12/31/2022	13,517	-417	-55	-23	N/A
9/30/2022	12,829	-414	-463	-401	N/A
6/30/2022	12,827	-570	-582	-519	N/A
3/31/2022	12,814	-634	-560	-498	N/A
12/31/2021	12,426	-670	-752	-689	N/A
9/30/2021	11,608	-689	-557	-531	N/A
6/30/2021	10,624	-545	-424	-398	N/A
3/31/2021	9,222	-479	-290	-264	N/A
12/31/2020	8,203	-457	-143	-117	N/A
9/30/2020	6,908	-483	-57	-32	N/A
6/30/2020	5,656	-498	-370	-345	N/A
3/31/2020	4,872	-506	-590	-565	N/A
12/31/2019	3,952	-500	-537	-512	N/A
9/30/2019	3,162	-468	-583	-569	N/A
6/30/2019	2,549	-470	-461	-447	N/A
3/31/2019	2,111	-457	-395	-384	N/A
12/31/2018	1,786	-380	-358	-343	N/A
9/30/2018	1,504	-319	-278	-275	N/A
6/30/2018	1,255	-255	-123	-114	N/A
3/31/2018	1,094	-229	N/A	-153	N/A
12/31/2017	959	-249	N/A	-204	N/A
12/31/2016	874	-418	N/A	-389	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: Er zijn onvoldoende gegevens om te bepalen of de verwachte winstgroei van YI boven de spaarquote ( 2.5% ) ligt.

Winst versus markt: Er zijn onvoldoende gegevens om te bepalen of de winst van YI naar verwachting sneller zal groeien dan de markt US

Hoge groeiwinsten: Er zijn onvoldoende gegevens om te bepalen of de winst van YI naar verwachting de komende 3 jaar aanzienlijk zal groeien.

Omzet versus markt: De omzet van YI ( 10.2% per jaar) zal naar verwachting sneller groeien dan de markt US ( 8.7% per jaar).

Hoge groei-inkomsten: De omzet van YI ( 10.2% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van YI naar verwachting over 3 jaar hoog zal zijn

111 Toekomstige groei

Future criteriumcontroles 1/6

Belangrijke informatie

Recente toekomstige groei-updates

111, Inc. Provides Revenue Guidance

111, Inc. Provides Preliminary Revenue Guidance for the Third Quarter of 2021

111, Inc. Provides Revenue Guidance for the Second Quarter of 2021

111, Inc. Provides Earnings Guidance for the First Quarter of 2021

Recent updates

111, Inc. Announces Receipt of Notification from Nasdaq

111, Inc. Announces Receipt of Notification from Nasdaq

A Look At The Intrinsic Value Of 111, Inc. (NASDAQ:YI)

111, Inc. to Report Q2, 2024 Results on Aug 29, 2024

111, Inc. announced delayed 20-F filing

111, Inc. to Report Q4, 2023 Results on Mar 21, 2024

Gang Yu, Junling Liu and Shanghai Guosheng Capital Management Co., Ltd. cancelled the unsolicited preliminary non-binding proposal letter to acquire 111, Inc. (NasdaqGM:YI) from Gang Yu, Junling Liu and others.

Gang Yu, Junling Liu and Shanghai Guosheng Capital Management Co., Ltd. cancelled the unsolicited preliminary non-binding proposal letter to acquire 111, Inc. (NasdaqGM:YI) from Gang Yu, Junling Liu and others.

New minor risk - Share price stability

Third quarter 2023 earnings released

111, Inc. to Report Q3, 2023 Results on Nov 30, 2023

Second quarter 2023 earnings released: CN¥0.68 loss per share (vs CN¥1.14 loss in 2Q 2022)

111, Inc. to Report Q2, 2023 Results on Aug 24, 2023

First quarter 2023 earnings released: CN¥0.38 loss per share (vs CN¥1.33 loss in 1Q 2022)

111, Inc. to Report Q1, 2023 Results on Jun 15, 2023

Full year 2022 earnings released: CN¥5.00 loss per share (vs CN¥8.08 loss in FY 2021)

Third quarter 2022 earnings released: CN¥1.16 loss per share (vs CN¥3.05 loss in 3Q 2021)

Insufficient new directors

111, Inc. to Report Q3, 2022 Results on Dec 01, 2022

111, Inc. Announces Appointment of Independent Financial Advisor and Legal Counsel to the Special Committee

Second quarter 2022 earnings released

111, Inc. Provides Revenue Guidance

111 Non-GAAP EPS of -$0.14, revenue of $453.4M

111, Inc. to Report Q2, 2022 Results on Aug 25, 2022

111, Inc.'s Inexorable Drive Towards Profitability

First quarter 2022 earnings released

Insufficient new directors

111, Inc. to Report Q1, 2022 Results on Jun 16, 2022

Full year 2021 earnings: Revenues in line with analyst expectations

111, Inc. to Report Q4, 2021 Results on Mar 17, 2022

Third quarter 2021 earnings released

Solid Earnings, Modest Buyback Fail To Boost Drug Seller 111, Inc.

111, Inc. (NasdaqGM:YI) announces an Equity Buyback for $10 million worth of its shares.

Second quarter 2021 earnings released

111, Inc. Provides Preliminary Revenue Guidance for the Third Quarter of 2021

Health Check: How Prudently Does 111 (NASDAQ:YI) Use Debt?

111, Inc.: Undervalued After Recent Unjustified Share Price Collapse; 50% Upside

First quarter 2021 earnings released: CN¥1.77 loss per share (vs CN¥1.52 loss in 1Q 2020)

111, Inc. Provides Revenue Guidance for the Second Quarter of 2021

Full year 2020 earnings released: CN¥5.54 loss per share (vs CN¥6.11 loss in FY 2019)

Is 111 (NASDAQ:YI) A Risky Investment?

Full year 2020 earnings released: CN¥5.54 loss per share (vs CN¥6.11 loss in FY 2019)

111, Inc. Provides Earnings Guidance for the First Quarter of 2021

Could The 111, Inc. (NASDAQ:YI) Ownership Structure Tell Us Something Useful?

111, Inc. to Report Q4, 2020 Results on Mar 18, 2021

111, Inc. Signs Strategic Cooperation Agreement with Jilin Baiyi Doctor Group to Create & Deliver New Models for Internet Medical Services

New 90-day high: US$12.70

Did You Miss 111's (NASDAQ:YI) 70% Share Price Gain?

New 90-day high: US$7.62

111 (NASDAQ:YI) Has Debt But No Earnings; Should You Worry?

Why 111, Inc. (NASDAQ:YI) Could Be Worth Watching

Third quarter 2020 earnings released: CN¥1.32 loss per share

111 reports Q3 results, provides Q4 revenue guidance

111, Inc.: Cheap But Risky And Controlled By Founders

New 90-day high: US$7.45

111, Inc. Announces Management Changes

111, Inc. and Shanghai Uniondrug Information Technology Join Hands to Advance Innovation in Commercial Insurance Payment

New 90-day low - US$5.96

First half earnings released

111, Inc. to Report Q2, 2020 Results on Aug 20, 2020

New 90-day low - US$6.14

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven